The market value is 16.78 billion!

On October 26, Huiyu Pharmaceutical (stock code 688553) was officially listed on the Science and Technology Innovation Board.
The company's current issue price was 38.
87 yuan per share.
The original plan to raise 1.
907 billion yuan, the actual total raised 2.
472 billion yuan, as of the closing exchange The corresponding market value of Uni-Pharmaceutical is 16.
78 billion
.

As a R&D-driven pharmaceutical company, Huiyu Pharmaceuticals has increased its R&D investment year by year, and the number of R&D personnel has increased.
According to the latest prospectus, the company currently has 87 research projects, of which 10 are Class 1 new drugs and 1 is an improved new drug; Seven injections were approved for production and deemed to have been reviewed, and six were included in the national centralized procurement and all won the bid
.

Revenue of 1.
392 billion yuan in the first three quarters! Huiyu Pharmaceutical's performance continues to grow at a high rate

Revenue of 1.
392 billion yuan in the first three quarters! Huiyu Pharmaceutical's performance continues to grow at a high rate

The founder of Huiyu Pharmaceuticals, Dr.
Zhao Ding, was born in 1985.
He graduated with a PhD in Pharmacology from Cambridge University in the United Kingdom at the age of 24.
He returned to China in 2010 and founded Sichuan Huiyu Pharmaceuticals.
In 2014, he passed British GMP and China GMP successively, and started in the United Kingdom in 2015.
Sell ​​products
.

According to prospectus data, in recent years, Huiyu Pharmaceutical's revenue has increased year by year.
In 2020, it will break 1 billion yuan for the first time, reaching 1.
364 billion yuan, an increase of 92.
94% over the same period of the previous year; in the first half of 2021, the company's revenue will reach 885 million yuan.
An increase of 51.
16% over the same period of the previous year, sales revenue of 1.
392 billion yuan was achieved in the first three quarters
.

Huiyu Pharmaceutical's performance (unit: 100 million yuan)

Source: Prospectus

From the official website of Huiyu Pharmaceuticals, the mission of the founder, Dr.
Ding Zhao, to establish the company is to "provide patients around the world with drugs with exact curative effect, superb quality, and reasonable price, so that cancer can become a controllable "chronic disease
.

" Through consistency evaluation With the legal mechanism of centralized procurement by the country, the price of high-priced anti-cancer original research drugs abroad has been reduced, allowing patients to use high-quality drugs at a lower price

Pemetrexed disodium for injection, which was approved for production under the imitation 4 categories at the end of 2017, is Huiyu Pharmaceutical’s first over-evaluated product and the first domestically over-evaluated injection.
It was included in the 4+7 volume procurement in 2018.
Huiyu The pharmaceutical company successfully won the bid and successfully won the bid in the centralized procurement of the alliance area with a very small drop.
At the same time, the price of the original research product of Eli Lilly was reduced by nearly 80%
.

Before the centralized procurement, the market of Pemetrexed was mainly occupied by Hausen, Qilu and Eli Lilly.
The volume purchase helped Huiyu Pharmaceutical's sales to rise rapidly, and at the same time, the company's performance showed rapid growth
.

Soaring nearly 60%! Increased revenue drives R&D speed up

Soaring nearly 60%! Increased revenue drives R&D speed up

As a R&D-driven comprehensive pharmaceutical company, Huiyu Pharmaceuticals attaches great importance to R&D and innovation
.

In recent years, the company's R&D expenses and the number of R&D personnel have continued to rise.

As of July 2021, Huiyu Pharmaceutical's innovative drug R&D team has nearly 100 people, and more than 60% have a master's degree or above.
The team’s technical backbones are from well-known overseas pharmaceutical companies, and they have a wealth of innovative drug R&D and management overseas.
Experience; most of the team members come from world-renowned universities such as Harvard University, Cambridge University, and Peking University
.

Huiyu Pharmaceutical R&D Investment

Source: Prospectus

Before 2019, Huiyu Pharmaceutical’s revenue was not high, but the company insisted on R&D and innovation, and R&D expenses accounted for a large proportion of revenue (158.
3% in 2017, 72.
1% in 2018).
After 2019, due to the increase in operating revenue Faster, the company’s R&D expenses as a percentage of operating revenues are declining year by year, but the absolute value of R&D investment still maintains a rapid growth, which will rise by nearly 60% in 2020, helping the research and development of innovative drugs
.

After years of technology accumulation, Huiyu Pharmaceuticals has established a number of advanced technologies and technology platforms, including a technology platform for the consistency evaluation of generic injections, a technology platform for the production and quality control of complex injections, a quality control technology platform for the production of raw materials, and production quality that meets EU standards.
Management system and efficient international registration system.
These technology platforms involve the company's R&D, production, and registration processes, and have an important impact on the industrialization of all the company's products
.

Huiyu Pharmaceutical plans to raise 1.
907 billion yuan this time, and the actual raised funds are 2.
472 billion yuan, mainly for the EU standard injection industrialization base (Phase II) project, the innovative drug research institute construction project and supplementary working capital
.

It is reported that the current construction project of the Institute of Innovative Drugs has two capped buildings, which are expected to be completed and put into operation in 2022, which can accommodate 1,500 R&D personnel, which will speed up the development of Huiyu's new drugs

Innovative Drug Research Institute Construction Project

Source: Huiyu Pharmaceutical's official website

87 projects are under development, 10 Class 1 new drugs are in force

87 projects are under development, 10 Class 1 new drugs are in force

Facing the changes in domestic pharmaceutical policies and market environment, Huiyu Pharmaceuticals reviewed the current situation and regarded innovative drugs as one of the core of the company's future development
.

Currently, the company has 87 projects under research, including 11 innovative drug projects (10 Class 1 new drugs, 1 improved new drug), 42 generic drug preparation projects, and 32 raw material drugs and excipient projects

In terms of innovative drugs, Huiyu Pharmaceuticals deeply analyzes the clinical vacancies in the oncology field, keeps up with industry trends and scientific research, and focuses on the global first-in-class and me-better varieties of similar products that have not yet entered the clinical research stage
.

In terms of bio-innovative drugs, it focuses on the research and development of anti-tumor drugs, especially tumor immunity-related drugs, involving multispecific antibodies, antibody-conjugated drugs (ADC), mRNA tumor vaccines, etc.

Part of Huiyu Pharmaceutical's innovative drugs under development

Source: Prospectus

According to data from Minai.
com, Huiyu Pharmaceuticals currently has 7 anti-tumor injections approved for production and deemed to have been reviewed, and the company is among the top three reviewed companies of the same variety, including pemetrexed disodium for injection and doxyl Hexai injection and azacitidine for injection are the first to be reviewed
.

Huiyu Pharmaceutical has approved products

Source: Huiyu Pharmaceutical's official website

Except for irinotecan, all other varieties are included in the national collection
.

Pemetrexed disodium was selected for 4+7 and alliance centralized procurement, azacitidine was selected for the third batch of centralized procurement, and oxaliplatin, paclitaxel, docetaxel, and bendamustine were selected for the fifth batch of centralized procurement.

Overseas, Huiyu Pharmaceutical passed the British GMP certification for the first time in 2014.
In 2015, its wholly-owned subsidiary, Haiyue Pharmaceutical, passed the EU drug release qualification certification.
In the same year, its own brand of anti-tumor injections achieved large-scale sales in the EU
.

At present, the company has more than 10 injections approved for listing in EU countries, and sold in more than 1,000 medical institutions overseas, including bendamustine, docetaxel, doxorubicin, irinotecan, oxaliplatin , Paclitaxel, pemetrexed, zoledronic acid, etc.

Some of Huiyu Pharmaceutical's varieties under review

Source: Meinenet MED2.
0 Chinese Drug Evaluation Database

According to data from Meinenet, the market size of terminal butylphthalide injections in China's public medical institutions in 2020 will be close to 4 billion yuan, and the market capacity of sodium valproate injection will exceed 1 billion yuan, and it has not yet entered centralized procurement
.

There is no generic approval for Puleshafu injection.
This is a chemokine receptor CXCR4 antagonist.
The original product was approved for import at the end of 2018.
Currently, 3 companies have reported production under the new classification, among which Huiyu Pharmaceutical It is the first company to report for property and is currently in the first round of data issuance
.

Starting a new journey in the capital market, Huiyu Pharmaceuticals has a promising future

Starting a new journey in the capital market, Huiyu Pharmaceuticals has a promising future

"To provide patients around the world with drugs with accurate curative effects, superb quality, and reasonable prices, so that cancer can become a controllable chronic disease.
" This is the mission of Huiyu Pharmaceuticals given by the times
.

In order to fulfill its mission, Huiyu Pharmaceuticals has not stopped in research and development.

Work hard, accumulate thinly
.
After years of hard work, Huiyu Pharmaceutical has built a rich product line in the field of injection generic drugs, occupying a certain position in the domestic and foreign markets
.

Domestically, the company’s products that have been included in the national centralized procurement are all newly approved for listing, and the market has not yet been opened.
By winning the bid through centralized procurement, a certain market can be guaranteed and market access problems can be solved; overseas, with The number of approved products has increased, and the company's overseas market share has gradually increased, laying the foundation for future innovative drugs to go overseas
.

Based on the present, looking forward to the future
.
With the continuous improvement of Huiyu Pharmaceutical's profitability, the company gradually shifts its focus to innovative drugs, and strives to realize the combination of innovation and innovation, and then the combination of innovation and imitation, and finally become an innovative R&D enterprise focusing on innovative drugs.

.

Huiyu Pharmaceutical’s successful issuance and listing on the A-share Sci-tech Innovation Board on the one hand has enhanced the company’s brand influence and industry awareness.
On the other hand, with the backing of raised funds, the company can increase and accelerate the R&D layout, while advancing the process of internationalization, achieving innovative development, his future is worth looking forward to!

Source: Mynet database, company official website and announcement

Note: Statistics as of October 26